These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12009576)

  • 1. Role of p53 in the sensitization of tumor cells to apoptotic cell death.
    Thiery J; Echchakir H; Dorothée G; Ameyar-Zazoua M; Haddada H; Mami-Chouaib F; Chouaib S
    Mol Immunol; 2002 May; 38(12-13):977-80. PubMed ID: 12009576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.
    Chouaib S; Thiery J; Gati A; Guerra N; El Behi M; Dorothée G; Mami-Chouaib F; Bellet D; Caignard A
    Tissue Antigens; 2002 Oct; 60(4):273-81. PubMed ID: 12472656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tumor/cytotoxic effector cross-talk in the control of tumor susceptibility to lysis].
    Gati A; Dorothée G; Thiéry J; Guerra N; Richon C; Gaudin C; Mami-Chouaib F; Caignard A; Diarra-Mehrpour M; Chouaib S
    Bull Cancer; 2003; 90(8-9):686-94. PubMed ID: 14609757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.
    Frost P; Caliliw R; Belldegrun A; Bonavida B
    Int J Oncol; 2003 Feb; 22(2):431-7. PubMed ID: 12527945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. γδ T cells in cancer immunotherapy.
    Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
    Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How do tumors actively escape from host immunosurveillance?
    Wilczyński JR; Duechler M
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):435-48. PubMed ID: 20922572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing.
    Radoja S; Frey AB
    Mol Med; 2000 Jun; 6(6):465-79. PubMed ID: 10972084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
    Ahmad M; Rees RC; Ali SA
    Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?
    Salih HR; Nüssler V
    Eur J Med Res; 2001 Aug; 6(8):323-32. PubMed ID: 11549514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
    Zhu J; Petit PF; Van den Eynde BJ
    Cancer Immunol Immunother; 2019 May; 68(5):835-847. PubMed ID: 30406374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
    Spranger S
    Int Immunol; 2016 Aug; 28(8):383-91. PubMed ID: 26989092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunology for the clinician.
    Weiner LM
    Clin Adv Hematol Oncol; 2015 May; 13(5):299-306. PubMed ID: 26352774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression.
    Egilmez NK; Kilinc MO
    Arch Immunol Ther Exp (Warsz); 2010 Dec; 58(6):399-405. PubMed ID: 20872283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor infiltrating regulatory T cells: tractable targets for immunotherapy.
    Khan AR; Dovedi SJ; Wilkinson RW; Pritchard DI
    Int Rev Immunol; 2010 Oct; 29(5):461-84. PubMed ID: 20839911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity.
    Frost P; Ng CP; Belldegrun A; Bonavida B
    Cell Immunol; 1997 Aug; 180(1):70-83. PubMed ID: 9316641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
    Ioannides CG; Whiteside TL
    Clin Immunol Immunopathol; 1993 Feb; 66(2):91-106. PubMed ID: 8453790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.